Revolution Medicines $345 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the underwriters in connection with a public offering at $22 per share of 15,681,818 shares of common stock of Revolution Medicines, Inc. (which includes the exercise in full by the underwriters of their option to purchase up to 2,045,454 additional shares), for total gross proceeds of $345 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.”
Based in Redwood City, California, Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow, Bex Childress and Dove Barbanel. The intellectual property and technology transactions team included partner David R. Bauer and associate Adrian Rabin. The tax team included partner Michael Farber and associate Betsy Johnson. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.